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This review highlights the genotype-phenotype relationship of the genetic immunodeficiency disease leukocyte
adhesion deficiency (LAD) in humans, dogs, cattle, and mice, and provides assessment of the opportunities that each
animal species provides in the understanding of leukocyte biology and in developing new therapeutic approaches to
LAD in humans. This comparison is important since animal models of genetic diseases in humans provide the oppor-
tunity to test new therapeutic approaches in an appropriate, disease-specific model. The success of this approach is
dependent on the relationship of the phenotype in the animal to the phenotype of the disease in humans.
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Leukocyte adhesion deficiency (LAD) is a genetic immunode-
ficiency disease in humans that is characterized by defects in the
leukocyte adhesion cascade. Currently, three types of LAD have
been identified. In LAD type-I disease, the most common type,
deficiency of the integrin β2 subunit (CD18) is responsible for
the disease phenotype (4, 6). In LAD type-II disease, absence of
the selectin ligand, SleX, affects leukocyte rolling (21). Recent
findings indicate presence of a third form of LAD (type III),
which is caused by defects in G protein-coupled receptor-medi-
ated integrin activation (3, 41). This review will focus on LAD
type-I disease, designated LAD, and its corresponding animal
models.
Clinically, LAD is characterized by recurrent, life-threatening,
bacterial infections (4). The increased susceptibility to bacterial
infections associated with LAD results from the inability of leu-
kocytes (especially neutrophils) to adhere to the blood vessel
wall and migrate to sites of infection (6). These adhesion defects
stem from mutations in the common CD18 subunit of the leuko-
cyte integrin family of molecules that is required for surface ex-
pression of the CD11/CD18 leukocyte integrin heterodimers
(65).
During the past 20 years, naturally occurring forms of LAD in
two other animal species, Irish Setter dogs and Holstein cattle,
have been described (36, 59). In addition, a CD18 gene-targeted
mouse model has been generated (62, 73). All three animal spe-
cies with LAD display a disease phenotype similar to the human
form of the disease, thus confirming the important contribution
of the CD11/CD18 molecules to leukocyte adherence reactions in
inflammation and host defense. However, each species offers
unique insights into the pathology of LAD. Since animal models
of human disease often fail to match the phenotype of the dis-
ease in humans, it is essential to characterize the specific mani-
festations of LAD in each species. This is especially pertinent if
these animal models are proposed for use in testing new thera-
peutic approaches to LAD.
Leukocyte Integrins
Defects in the leukocyte integrin CD18, which result in the in-
ability to express functional CD11/CD18 leukocyte integrin
heterodimers on the cell surface, form the basis for type-I LAD dis-
ease in humans and animals. The leukocyte integrins are mem-
brane glycoproteins composed of non-covalently associated
CD11 and CD18 subunits that mediate cell-cell and cell-matrix in-
teractions (45). The CD18 molecule heterodimerizes with four dis-
tinct CD11 subunits to form CD11a/CD18 (leukocyte
function-associated antigen 1 [LFA-1]), CD11b/CD18 (macrophage
antigen 1 [Mac-1]), CD11c/CD18 (p150,95) and CD11d/CD18
(αDβ2) (Fig. 1) (26).
Prior to processing, the CD11 and CD18 subunits precursors
form a heterodimer intracellularly. In LAD patients, lack of
CD18 or presence of a mutant CD18 subunit results in failure of
dimerization and transport of the CD11 subunit to the cell sur-
face, despite synthesis of a normal CD11 subunit precursor.
Thus, defects in the CD18 molecules result in failure to express
all four CD11 subunits on the leukocyte surface (6).
The CD11 subunits of the leukocyte integrin family are selec-
tively expressed on distinct populations of leukocytes where they
mediate a variety of adhesion-related functions. The CD11a sub-
unit is expressed at high levels on B and T lymphocytes, and at
lower levels on monocytes, macrophages, and neutrophils (61).
This pattern of CD11a/CD18 expression is consistent among the
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various species. The CD11a/CD18 complexes enable T lympho-
cytes to adhere to target cells and mediate cytotoxic T-lymphocyte
activity (61). Neutrophils, monocytes, and certain lymphocyte sub-
populations express CD11b at high levels (18, 51). The CD11b/
CD18 complex mediates diverse adhesion-related functions, in-
cluding chemotaxis and phagocytosis. The expression of CD11c/
CD18 is restricted to leukocytes derived from myeloid lineages,
as well as subsets of T and B lymphocytes and natural killer
(NK) cells. The CD11c/CD18 integrin mediates the binding of
iC3b-opsonized particles, cytotoxic T lymphocyte-mediated kill-
ing, and chemotaxis of myeloid cells (15). The expression of
CD11d/CD18 is limited to macrophages and some lymphocyte
populations (19).
Leukocyte Adhesion Deficiency in
Humans
Clinical and histopathologic features of LAD. The sever-
ity of neutrophil function abnormalities and clinical infectious
complications among patients with LAD are directly related to
the degree of glycoprotein deficiency. Leukocyte adhesion defi-
ciency has been categorized as moderate or severe according to
quantitative differences in expression of the leukocyte integrins
on the leukocyte surface (4). Patients with moderate deficiency ex-
press 1 to 10% of normal CD11/CD18 levels, whereas patients
with severe deficiency typically express < 1% of normal CD11/
CD18 levels (31). Severely affected patients have a profound de-
fect in neutrophil immigration into tissues and suffer from ex-
tensive bacterial infections. Historically, approximately 75% of
severely affected patients die before the age of 2 years (24). The
prognosis appears better for patients with moderate phenotype;
however, only 25% of patients with the moderate phenotype of
LAD are predicted to survive to age 40 (4, 23).
In children with the severe deficiency phenotype of LAD, the
clinical manifestations of LAD typically begin in infancy or early
childhood. Delayed umbilical cord detachment and accompany-
ing omphalitis is a frequent finding, and often represents the ini-
tial presentation of the disease. During the early years of life of
children with the severe type of LAD, these infections take the
form of otitis media, perianal abscesses, and non-healing, cuta-
neous wounds. Recurrent, necrotic, indolent infections of soft tis-
sues involving the skin, mucous membranes, and
gastrointestinal and respiratory tracts also are common. The
skin lesions are frequently insidious in that they start with a
small, erythematous, nonpustular lesion, which then progresses
to a large wound with an ulcerative crater (Fig. 2, panel A).
These wounds heal slowly despite antibiotic therapy (4, 6). Typi-
cally, the histologic features of skin wounds from LAD patients
are characterized by ulceration with extensive necrosis, and are
accompanied by the presence of neutrophils in the blood vessels
but not in the surrounding tissue. Severe chronic gingivitis and
rapidly progressive periodontitis are chronic problems in pa-
tients who survive infancy (Fig. 2, panel B). Subsequently, these
patients develop alveolar bone loss and partial or total loss of
deciduous and permanent dentitions (4, 70).
Infections are less frequent and usually less severe in patients
with the moderate deficiency phenotype of LAD, although in
terms of location and evolution, the infections themselves are
similar to those in children with the severe phenotype. Recur-
rent skin/subcutaneous infections, stomatitis, gingivitis, otitis, si-
nusitis, and pneumonia have been associated with this moderate
phenotype of LAD (4).
Although the leukocyte integrins on lymphocytes, monocytes,
and neutrophils are deficient in patients with LAD, the predomi-
nant clinical manifestations are those of a phagocytic rather
than a lymphocytic disorder. This is likely because neutrophils
are principally dependent on the CD18 integrins for firm adhe-
sion and transendothelial migration, whereas lymphocytes have
overlapping or redundant adhesion cascades (57). This inability
of neutrophils to adhere to the vessel wall and migrate to the site
of infection results in the absence of a suppurative inflammatory
reaction at sites of infection (Fig. 3A).
Results of in vitro and in vivo neutrophil functional studies
are strikingly abnormal in LAD patients. Adhesion and adhe-
sion-related functions such as chemotaxis reflect the most pro-
found impairments. The magnitude of the defective in vitro
responses is related to the level of expression of the CD11/
CD18 complexes. In vivo skin window tests of leukocyte mobili-
zation have confirmed the presence of a striking defect in leu-
kocyte migration.
A variety of in vitro abnormalities in lymphocyte function
also have been documented in LAD patients, although the clini-
Figure 1. Schematic diagram of normal CD11/CD18 heterodimerization
and expression on cell surface. The CD11 and CD18 genes are tran-
scribed, translated, and non-covalently associated before processing and
membrane insertion. In leukocytes from leukocyte adhesion deficiency
(LAD)-affected patients, defects in the CD18 gene result in the inabil-
ity to express all four CD11/CD18 heterodimers on the cell surface.
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Figure 2. Pathology of LAD in affected species. (A) Severe skin wound and (B) gingivitis in LAD patients. (C) Omphalitis and (D) gingivitis in canine
LAD-affected dogs. (E) Intestinal subserosal fibrosis (arrow) and (F) an ulcer on the tongue (arrow) in bovine LAD-affected cattle. (G) A Cd18 -/- mouse
showing crusting dermatitis abscess in the neck and (H) peri-orbital ulcerative dermatitis.
Figure 3. Histologic findings of LAD in affected species (H&E staining). (A) Photomicrograph of a section of skin from a LAD-affected patient
showing bacterial colonies (arrows) and lack of neutrophils in the ulcerated area (400×). (B) Photomicrograph of a section from the anal gland of a dog
with canine LAD; notice neutrophils in hyperplastic mucosal epithelium (400×). (C) Photomicrograph of a section of ulcerated intestinal mucosa with
numerous congested vessels containing neutrophils from a cow with bovine LAD (100×). (D) Photomicrograph of a section of skin from a Cd18-/- mouse.
Notice venule at the site of inflammation showing neutrophils (arrows) in the vessel but none in the tissue (∼400×).
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cal relevance of these abnormalities is less clear. The T lympho-
cytes from LAD patients respond poorly to low concentrations
of lectins and anti-CD3 monoclonal antibodies, and antigen-in-
duced T-cell proliferation to low concentrations of antigens also
is diminished (12, 44).
Molecular defects in LAD patients. Leukocyte adhesion
deficiency was first recognized in the early 1980s when a num-
ber of children who suffered from acute infections and whose
neutrophils lacked a protein variably reported as 95 to 138 kD in
size were reported (11, reviewed in 5). Subsequent studies using
monoclonal antibodies identified the missing protein as the leu-
kocyte integrin CD18 molecule. Springer (65) had previously
proposed that the primary defect in the patients resided in the
CD18 subunit, which is shared by all CD11 subunits, and that
CD18 was required for CD11/CD18 heterodimer formation and
surface expression. After the cloning of the CD18 cDNA (43, 46),
mutations in the CD18 gene in a number of patients with LAD
were reported (7, 42, 64). Since that time, more than 40 muta-
tions have been identified in LAD patients, including missense,
nonsense, splice site, insertion, and deletion mutations (5, 42). In
addition to the nonsense mutations that preclude translation of
a functional CD18 protein, most mutations arise in locations
important for CD18 heterodimerization with CD11, or in regions
important for CD18 function. Since the CD11 proteins contain
several domains important for function, the lack of a functional
CD11/CD18 heterodimer on the surface of the leukocyte pre-
cludes CD11, as well as CD18 function. If consanguinity is ex-
cluded, patients with LAD are typically compound heterozygotes
with a different CD18 mutation in each allele (5, 32).
Diagnosis of LAD. Although a presumptive diagnosis of LAD
can be suspected on the basis of delayed umbilical cord separa-
tion, non-healing skin wounds, and an extremely high white
blood cell (WBC) count consisting mainly of mature neutrophils,
the diagnosis of LAD is typically confirmed by use of flow
cytometric analysis of CD18 expression on the patient’s leuko-
cytes (Fig. 4, panel A). As described earlier, patients with LAD
are categorized as having moderate (1 to 10%) or severe (< 1%)
disease, depending on the level of CD18 expression on the leuko-
cyte surface. Although use of flow cytometric analysis detects
most CD18 mutations, variant cases have been described in
which the DNA mutation allows expression of the CD18 protein;
however, the CD11/CD18 dimer is not fully functional (49). In
these particular cases, demonstration of leukocyte dysfunction is
carried out using in vitro tests such as chemotaxis or adherence
assays. Additionally, DNA sequencing of the patient’s CD18 gene
typically confirms the presence of mutations in the CD18 sub-
unit.
Treatment of LAD. Treatment of LAD depends on the sever-
ity of symptoms. Long-term antibiotic prophylaxis appears to de-
crease the frequency of infections; however, this therapy does not
prevent episodes of severe infection. During episodes of severe
infection, infusions of donor granulocytes have been used with
some success. However, antibiotic treatments and granulocyte
infusions represent only supportive care. Curative therapy for
LAD requires hematopoietic stem cell transplantation.
Allogeneic hematopoietic stem cell transplantation is recom-
mended for all patients with severe deficiency LAD who have
matched sibling donors. Transplantation has also been pro-
posed for patients with the moderate phenotype of LAD, since
these patients also have decreased life-span (67). However,
Figure 4. Comparison of LAD disease by use of flow cytometric analy-
sis in the severe phenotype of a humans (severe LAD), Irish Setter dogs
(CLAD), Holstein cattle (BLAD), and Cd18-/- mice. Neutrophils were
isolated from the peripheral blood of all four species and were stained
with fluorescently labeled control or anti-CD18 monoclonal antibodies
and were analyzed by use of flow cytometry.
since only 25% of LAD patients will have a matched sibling do-
nor, human leukocyte antigen (HLA) non-identical donors such
as parents or other siblings have been explored as a source of
donor cells for LAD patients (47, 67). Transplants in this set-
ting are accompanied by a considerably higher incidence of
graft rejection and graft-versus-host disease compared with
those of matched sibling donor transplants (67). In addition, al-
ternative donor stem cell sources for transplantation, including
cord blood (66), matched related, matched unrelated, and one-
haplotype mismatched related donor hematopoietic stem cells,
have been used (22).
In 1999, two patients with the severe deficiency form of LAD
were treated in a human gene therapy clinical trial (10). Mobi-
lized, peripheral blood stem cells (PBSC) were collected from the
LAD patients. The CD34+ hematopoietic stem cell fraction was
selected and incubated with a retroviral vector harboring the
CD18 cDNA. The CD34+ gene-corrected hematopoietic stem cells
were re-infused into the patients in the form of an autologous
transplant. In both patients, correction of up to 0.04% of the pa-
tients’ myeloid cells was apparent two weeks after the infusion
of the gene-corrected cells. However, CD18+ neutrophils were un-
detectable in the peripheral blood after 63 days post-infusion of
transduced cells. To achieve sufficient numbers of CD18+ neutro-
phils for this treatment to represent a therapeutic option, fur-
ther advances in vector design and transduction conditions, and
the possible use of myeloablation are likely to be required.
Leukocyte Adhesion Deficiency in Irish
Setter Dogs
Clinical and histopathologic features. In 1975, an 8-
week-old male Irish Setter dog with a clinical history of recur-
rent, life-threatening bacterial infections was described (58, 60).
Assessment of leukocyte function in the affected dog revealed
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significant decrease in neutrophil adherence to plastic, glass,
and nylon wool (59). Random migration, chemotaxis, and aggre-
gation of neutrophils in response to phorbol myristate acetate
also were impaired (60). These in vitro results led to the designa-
tion of the disease as “canine granulocytopathy syndrome” (59).
In 1987, Giger and colleagues (27) described an Irish Setter-
type (mixed-breed) dog with a disease phenotype similar to that
of the dog with canine granulocytopathy syndrome. Flow
cytometric analysis revealed severe deficiency of the CD11/CD18
leukocyte surface expression, similar to the situation described
in humans, and the disease was given the designation of canine
leukocyte adhesion deficiency or CLAD (27).
Canine LAD has subsequently been described in Irish Red
and White Setters (20, 25). In all setter breeds, clinical evidence
of disease in CLAD-affected dogs is manifested shortly after
birth, with development of omphalitis or umbilical abscess, fol-
lowed by frequent, severe bacterial infections (Fig. 2, panel C).
These episodes are typically accompanied by fever. The subse-
quent clinical course in dogs with CLAD is quite uniform, with
marked neutrophilic leukocytosis, severe gingivitis, lymphaden-
opathy, poor wound healing, and episodes of infection manifest-
ing as pyrexia and anorexia (Fig. 2, panel D). In dogs with CLAD,
development of hypertrophic osteodystrophy with physeal swell-
ing also has been described (16, 68). Skin lesions are a particu-
larly common finding in CLAD-affected dogs. Microscopically,
there is overlying epidermal ulceration with abundant necrosis
and evidence of bacterial infection. Multiple large abscesses are
frequently present in the dermis (68). In contrast to the histologic
findings in LAD patients, neutrophil infiltration into the infected
site is present in dogs with CLAD (Fig. 3B). In general, the disease
manifestations in CLAD-affected dogs are consistent with the re-
ported symptoms in children with the severe deficiency phenotype
of LAD (68, 69).
Hematologic studies in dogs with CLAD reveal persistent leu-
kocytosis beginning as early as one week of age, with neutro-
phils constituting up to 90% of the leukocytes in circulation (68).
The bone marrow is hypercellular, with increased numbers of
granulocytic myeloid precursors.
Molecular defect in CLAD dogs. The clinical manifesta-
tions of CLAD are caused by severe deficiency in expression of
the integrin CD18 molecule on the leukocyte surface, similar to
the flow cytometric findings in humans with the severe defi-
ciency form of LAD (Fig. 4, panel B). The CD18 cDNA sequences
from CLAD-affected dogs indicate a single nucleotide G-to-C
transversion at position 107, which leads to a replacement of cys-
teine by serine at residue 36 (C36S) in the N-terminal extracel-
lular portion of the CD18 protein (39). Since this cysteine
residue is highly conserved among the human, dog, pig, and
mouse CD18 subunits, the substitution of serine for cysteine
likely results in the disruption of a disulfide bond and aberrant
tertiary structure culminating in severe defects in CD11/CD18
heterodimer formation. All affected dogs have been documented
to be homozygous for the C36S mutation (20, 39). Canine LAD is
transmitted in the same autosomal recessive manner as is hu-
man LAD.
Diagnosis of CLAD. Canine LAD has only been reported in
the highly related Irish Setter (68) and Irish Red and White Setter
breeds (20, 25). Dogs of these breeds presenting with recurrent in-
fections should be tested for CLAD. Leukocytes from dogs sus-
pected of having CLAD can be assessed by use of flow cytometric
analysis for CD18 expression (Fig. 4, panel B). Initial screening of
CLAD carriers can also be done by use of flow cytometry; however,
confirmation of carrier status requires DNA testing using an oligo-
nucleotide ligation assay (39), pyrosequencing (40), or DNA se-
quencing (16). Commercial laboratory testing for CLAD carrier
status is now available (Optigen LLC, New York, N.Y.).
Treatment of CLAD. Treatment options for dogs with a diag-
nosis of CLAD are similar to those for humans with LAD. Antibi-
otic prophylaxis at the onset of clinical signs of CLAD appears to
decrease the frequency of infections; however, most CLAD-affected
dogs typically die from infection complications by six months of
age (68). Given the rapid presentation and severity of CLAD and
the limited treatment options available in the community, most
dogs presenting with the disease are ultimately euthanized.
Recently, matched related donor bone marrow transplantation
in CLAD-affected dogs has been described (17). In that study, re-
cipient CLAD-affected pups received a minimal myeloablative
conditioning regimen prior to bone marrow transplantation, and
a short (two-month) posttransplantation immunosuppressive
regimen. A total of 12 CLAD-affected dogs have been followed for
one year, and 11 display stable donor:host chimerism, in which 5
to 90% of the leukocytes are CD18+, and thus, are donor derived
(9). These dogs have remained free of all signs of CLAD since the
time of engraftment. Thus, the mixed chimerism state is suffi-
cient to protect the dogs from clinical disease, and results in re-
versal of the disease phenotype (17).
Leukocyte Adhesion Deficiency in
Holstein Cattle
Clinical and histopathologic features. In 1983, a 1-year-
old Holstein heifer with a syndrome consisting of fever, diarrhea,
and marked neutrophilia was described. The disease was re-
ferred to as “bovine granulocytopathy syndrome”(29). Calves
with the disease displayed clinical signs that were almost iden-
tical to those of dogs with canine granulocytopathy syndrome
and of children with the severe deficiency phenotype of LAD.
Neutrophil functional activities associated with migration and
complement receptor type-3 function were notably impaired (29).
Immunoblot analysis of neutrophil lysates from an affected calf
revealed total deficiency of CD11b (36). Subsequent studies con-
firmed that bovine granulocytopathy syndrome was the bovine
analog of human LAD, and the disease was re-named bovine
leukocyte adhesion deficiency (BLAD [56]).
Major clinical features in BLAD-affected cattle are recurrent
pneumonia, ulcerative stomatitis, enteritis with bacterial over-
growth, periodontitis, loss of teeth, delayed wound healing, and
failure of suppuration (Fig. 2, panels E and F) (37, 54). Mucosal
surfaces of the oral cavity and respiratory and gastrointestinal
tracts are most commonly affected, presumably due to the in-
tense bacterial colonization on these surfaces. Microscopically,
neutrophils are present in numerous congested vessels and the
splenic red pulp, but not in surrounding tissues of ulcerated in-
testinal mucosa and Peyer’s patch areas (Fig. 3C). Such affected
calves are typically unremarkable at birth; however, with expo-
sure to microbes in their environment, they develop persistent,
progressive neutrophilia, and eventually become unthrifty. Un-
treated BLAD-affected calves frequently die in the first year of
life, as is the case in dogs with the severe phenotype of CLAD.
Analysis of blood samples from BLAD-affected calves revealed
chronic progressive neutrophilia (> 80,000 cells/µl); normal cattle
Leukocyte adhesion deficiency disease in humans and animals
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have a total WBC count of approximately 4,000 cells/µl (48). Re-
ports of neutrophil counts in excess of 200,000 cells/µl of blood
are not uncommon in cattle with BLAD (48). Bone marrow ex-
amination of BLAD-affected cattle revealed myeloid hyperplasia
with increased myeloid-to-erythroid ratio (28).
Similar to that for human LAD and CLAD, the physiologic basis
for BLAD is a deficiency in the functional chemotactic and phago-
cytic neutrophils. The impaired adhesion and failure of migration
of neutrophils into inflammatory sites prevents normal immune
reactions to invading pathogens. One exception to this impairment
is associated with bovine pneumonia where neutrophils enter the
airways and alveolar spaces in response to inflammatory stimuli
(2, 28, 36). In BLAD-affected cattle with acute bacterial infection,
CD18-dependent infiltration occurs in the bronchi, whereas CD18-
independent infiltration occurs in the alveoli (1, 2).
Molecular defects in BLAD cattle. Cloning and sequencing
of cDNA from normal and BLAD-affected cattle identified a
point mutation at position 383 in the cDNA of the CD18 gene, re-
sulting in the substitution of glycine for aspartic acid at amino
acid 128 (D128G) in the CD18 molecule (63). This mutation lies
within a highly conserved region in the extracellular domain
where at least 125 consecutive amino acids are similar in normal
human, canine, bovine, porcine, rat, and murine CD18 (63). To
date, all cattle in which BLAD was diagnosed that have been ge-
netically tested have been homozygous for the D128G allele. In-
terestingly, a mutation at amino acid 128 was also described in a
child with the severe deficiency phenotype of LAD. This muta-
tion resulted from a D128N mutation (50).
Diagnosis of BLAD. The diagnosis of BLAD in cattle is usu-
ally suspected from the characteristic clinical features, and is
confirmed by use of flow cytometric analysis that indicates se-
vere deficiency in CD18 expression on the leukocytes (Fig. 4,
panel C). For carrier typing, the D128G allele can be diagnosed
by use of a polymerase chain reaction (PCR)-based assay that is
performed by several commercial vendors (Immgen, Inc., Col-
lege Station, Tex.; GenMARK, De Forest, Wis.; VITA-TECH
Laboratories, Buffalo, N.Y.). In the original diagnostic studies of
BLAD, all cattle with the mutant allele were related to one bull
which, through use of artificial insemination, sired many calves
in the 1950s and 1960s (35). In 1990, the carrier frequency of
BLAD was estimated to be 15% among Holstein bulls and 6%
among Holstein cows in the United States. The carrier frequency
in Japan was estimated to be 12.6% and about 0.31%, respec-
tively. It is likely the carrier frequency has decreased substan-
tially over the past decade due to extensive carrier testing and
selective breeding of non-BLAD carriers.
Treatment of BLAD. Treatment of BLAD consists of antibi-
otic prophylaxis; however, death usually ensues from severe in-
fection of the alimentary tract. In one report (55), bone marrow
transplantation was attempted. In that study, 2.2 × 109 bone
marrow cells were aspirated from a clinically normal 4-year-old
Holstein cow and were infused into a nine-month-old Holstein
heifer with BLAD (55). Twelve months after bone marrow trans-
plantation, a small fluorescent region in the CD18+ area (esti-
mated to represent 0.3 to 0.5% of the neutrophils) was detected
using flow cytometry. The recipient heifer developed a transient
skin rash and diarrhea, then improved clinically over the ensu-
ing 28 months. The investigators concluded that the newly ex-
pressed donor CD18 cells caused mild graft-versus-host disease;
however, the CD18+ donor leukocytes led to improvement in the
clinical signs of BLAD in this heifer.
A “natural” cord blood transplant in dizygotic twins with
BLAD as a result of anastomosis of the chorioallantioic mem-
branes between the twins was described. Kehrli and colleagues
(34) found that each twin was born with two distinct populations
of CD18– and CD18+ leukocytes in circulation in approximately
equal proportions, presumably as a result of one twin having
BLAD and the other twin being a heterozygote for CD18 expres-
sion, with transplacental blood exchange through a placental
anastomosis (Fig. 5). On the basis of absence of recurrent infec-
tions, as few as 10% of CD18+ cells appeared to correct the BLAD
disease in the affected twin.
Leukocyte Adhesion Deficiency in
(CD18 gene-targeted) Mice
Clinical and histopathologic features. Gene targeting us-
ing homologous recombination in embryonic stem cells has been
done to generate mice with a homozygous knockout of the mu-
rine CD18 gene. In the first attempt, an insertion mutation in
the murine CD18 gene was generated and resulted in a hypo-
morphic rather than a null allele mutation (73). These hypomor-
phic mice, designated Itgb2tm1Bay, were created on a mixed
background of C57BL/6J and 129/Sv mice. The homozygous mu-
tants were viable and expressed 2 to 16% of normal CD18 levels
on the leukocyte surface (73). Hypomorphic mice had mild neutro-
philia, minimal to mild hyperplasia in spleen and bone marrow,
and impaired inflammatory response. The percentage of CD18
expression on the hypomorphic mouse leukocytes was similar to
that associated with the moderate phenotype of humans with
LAD (4, 23). When backcrossed on a PL/J strain, homozygous
mice developed a novel chronic inflammatory skin disease, with
hyperplasia of the epidermis. This dermatitis, similar to human
psoriasis, was observed only in the PL/J strain, and not in any
C57BL/6 or 129/Sv backcrosses (14). This dermatitis has not been
observed in humans, cattle, or dogs with LAD. Subsequent analy-
sis has revealed the inflammatory effect to be dependent on low-
level CD18 expression, not dependent on microbial flora, and
requiring two PL/J-specific loci (8). Recent work in these hypo-
morphic mice has focused on the role of CD4+ and CD18 T lym-
Figure 5. Flow cytometric analysis of CD18-positive and CD18-nega-
tive neutrophil proportions in circulation from non-identical
leukochimeric bovine twins. At one day after birth, each twin had roughly
equal leukocyte proportions of their own true genotype and that of their
twin’s genotype. One calf ’s true genotype (determined by use of poly-
merase chain reaction (PCR) analysis of a skin biopsy specimen) was
that of a homozygous BLAD-affected animal (CD18-/-); the other twin
was a heterozygote (CD18+/-) for the D128G CD18 allele. These twins
maintained normal health status throughout their lives.
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phocytes in the inflammatory process of the dermatitis (8, 38).
Mice with complete deficiency in CD18 (CD18 null mice, Cd18-/-
or Itgb2-/-) were subsequently generated (62). These mice, desig-
nated Itgb2tm2Bay and produced on a mixed C57BL/6J and 129/
Sv background, were less viable than hypomorphic mice, with 10
to 40% of the CD18 null newborns dying during the perinatal pe-
riod (62). The phenotype of the CD18 null mice more closely re-
sembles that of the severe deficiency type of LAD in humans.
The phenotype of these mice included chronic dermatitis due to
extensive bacterial infiltration, neutrophilia, increased immuno-
globulin concentrations, lymphadenopathy, and splenomegaly
(Fig. 2, G and H) (62). Few neutrophils were observed in the skin
of CD18 null mice, and the mice had a severe defect in T-cell pro-
liferation. The increased susceptibility to infection in CD18 mu-
tant mice again emphasizes the importance of neutrophils as an
antigen-independent first line of host defense.
The peripheral blood of Cd18-/- mice contained 6- to 11-fold more
neutrophils than those in normal littermates (53, 62). During
acute inflammation, the CD18 null mouse is able to recruit neutro-
phils into the lung and peritoneal cavities via a CD18-independent
manner (53); however, recruitment of neutrophils into the perito-
neal cavity appears to be markedly reduced compared with that
into the lung (71). In comparison, CD18-independent neutrophil
emigration into the lung, but not the peritoneum, was observed
during autopsy of a human patient with the severe form of LAD
who died from infection (30). Similar to that in all species with
LAD, myeloid hyperplasia is present in the bone marrow of the
Cd18-/- mice (62).
Molecular defect in CD18 gene-targeted mice. A hypo-
morphic and a null mutation in the CD18 gene have been gener-
ated in mice by use of gene targeting, resulting in either partial
or complete inactivation of the endogenous alleles of the mouse,
respectively (62, 73). In the hypomorphic gene-targeted mice, a
cryptic promoter was present in the targeting construct that re-
sulted in low-level CD18 transcription, leading to a proportional
deficiency rather than an absence of CD18 (73). A subsequent
gene replacement strategy was used to generate the null mutation
of CD18 gene. This construct disrupts the 5' boundary of exon 3,
thereby preventing the synthesis of the CD18 protein (62).
Diagnosis of murine LAD. Unlike the situation with hu-
mans, dogs, or cattle, mice with naturally occurring mutations in
CD18 have not been described to our knowledge. The aforemen-
tioned CD18 gene-targeted mice are available from Jackson
Laboratories (Bar Harbor, Maine), or from the original produc-
tion laboratories, as either the CD18 gene-targeted hypomorphic
form (TBASE: TG-000-01-274) or the CD18 null form (TBASE:
TG-000-030344). The particular mutation can be identified
through DNA analysis by use of Southern blot or PCR analysis.
Both models, as previously stated, have distinct pathologies,
some of which are dependent on the mouse strain background,
the PL/J strain in particular for the hypomorphic mouse. The
CD18 null form more closely resembles classical LAD.
Treatment of the murine LAD model. Although CD18 mu-
tant mice have been invaluable in the exploration of the pathol-
ogy of LAD disease, to our knowledge, treatment modalities such
as transplantation and gene therapy for reversal of the disease
phenotype of CD18 mutant mice have not been explored, in con-
trast to studies in man, cattle, and dogs. Rather, experiments in
CD18 mutant mice have typically involved agents designed to
examine the role of CD18 in the pathology of LAD disease or for
CD18 function. For example, CD18 null mice have been infected
with Streptococcus pneumoniae or Escherichia coli to study neu-
trophil emigration (52, 53). The role of CD18 in the immune re-
sponse was assessed in CD18 null mice after infection with
Listeria monocytogenes and the tick Anaplasma phagocytophila
(13, 74). The important role of the CD18 molecule in neutrophil
extravasation, attachment, and production, especially in the ex-
aggerated case of leukocytosis in LAD patients, was also ex-
plored in the CD18 null mouse by experimental transplantation
of bone marrow cells from these mice into wild-type mice (33,
72). Extrapolation from these studies has provided insights into
the pathophysiology and mechanism of LAD disease.
Discussion
The animal models of LAD presented here highlight the im-
portant contribution of each species to the study of LAD and leu-
kocyte biology in general. Although it is an artificial model, the
development of the CD18 mutant mouse allows faster genera-
tion times and larger numbers to study the development and
progress of LAD disease. The CD18 null mouse model in particu-
lar may be advantageous for the study aspects of the clinical dis-
ease that are more costly, or more cumbersome in the dog or cow
model, due to their size and difficulty in handling. For the study
of organ-specific neutrophil infiltration, Cd18-/- mice and BLAD-
affected cattle have been used in studies of acute pneumonia.
Both models support CD18-dependent and -independent mecha-
nisms of infiltration in regions of lung, which are similar to find-
ings in human LAD patients with pneumonia.
Despite the similarities of these models to human LAD, there
are some limitations when extrapolating these results to humans.
For example, mice differ from humans and large animals in sev-
eral aspects, including their small size, short life-span, and the
limited proliferative demand on hematopoietic stem cell and pro-
genitor compartments. During its lifetime, a mouse makes as
many neutrophils as a human makes in 2 h, a cow in 24 min, or a
dog in 4 h (Table 1). The neutrophil demands of humans are more
similar compared with those of dogs or cattle, than are those of
mice.
The CLAD model is particularly valuable for studying new
forms of hematopoietic stem cell transplantation and gene
therapy. Dogs have a long history of use in hematopoietic stem
cell transplantation, and the dog model has performed a critical
role in extension to human transplantation. In transplantation
studies, it is easy to cross histocompatibility barriers in mice
Table 1. Neutrophil demands of various species
Species Neutrophils Body weight (kg) Blood volume (ml) Neutrophil life Neutrophil production Life expectancy Neutrophil
per milliliter span (days) per day (years)  production in life time
Human    5 × 106 70 4,900 0.33  7.4 × 1010 80  2.2 × 1015
Cattle 2.3 × 106 636 47,700 0.33  3.3 × 1011 17  2.1 × 1015
Dog 7.4 × 106 18 1,550 0.33  3.5 × 1010 13  3.8 × 1013
Mouse 1.4 × 106 0.025 1.8 0.33 7.6 × 106 2 5.5 × 109
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and, and in general, there are fewer problems with graft rejec-
tion or fatal graft-versus-host disease. This is partially due to
less genetic variability in inbred strains of mice. Purpose-bred
dogs are more outbred than are mice, and therefore, offer a more
relevant model for the studies of the corresponding diseases in
humans in the field of transplantation biology.
In conclusion, we present three animal models used in the
study of LAD disease. Each of the animal models of LAD pro-
vides unique insights into the study of the pathology and mo-
lecular basis of LAD. The choice of a particular animal model
depends on the nature of the investigation.
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